Bristol-Myers Squibb Reports Fourth Quarter & Full Year 2016 Financial Results
Bristol-Myers Squibb Company (NYSE: BMY) reported results for the fourth quarter and full year 2016, which were highlighted by strong sales for key products Opdivo and Eliquis, regulatory approvals for Opdivo in the U.S. and Europe, and strategic transactions in oncology and fibrosis that further strengthened the company's pipeline. Bristol-Myers Squibb posted fourth quarter 2016 revenues of $5.2 billion, an increase of 22% compared to the same period a year ago. Global revenues increased 24% adjusted for foreign exchange impact. U.S. revenues increased 20% to $2.7 billion in the quarter compared to the same period a year ago. International revenues increased 25%. When adjusted for foreign exchange impact, international revenues increased 28%. For more on Bristol-Myers Squibb fourth quarter and full year 2016 financial results click on the picture below to read the complete release.